Антимюллеров гормон в дифференцировке, развитии и функции репродуктивной системы


Интеграция сведений о роли антимюллерова гормона (АМГ) в дифференцировке, развитии и функции репродуктивной системы позволяет заключить следующее. Половые клетки предопределяют биосинтез АМГ от зарождения до окончания функции репродуктивной системы. Вступление половых клеток в мейоз ограничивает синтез АМГ, обеспечивая его постоянный уровень в течение репродуктивной зрелости. С угасанием гаметогенеза синтез АМГ прекращается.

Об авторах

T Ustinkina

S Shustov

Список литературы

1. Дедов И.И., Семичева Т.В., Петеркова В.А. Половое развитие детей: норма и патология. М: Медицина 2002; 232.

2. Устинкина Т.И. Общие вопросы эндокринологии мужской половой системы: структурно-функциональная организация, этиопатогенез недостаточности и основные формы нарушений половых желез. Пробл эндокринол 2007; 53: 6: 34-40.

3. Устинкина Т.И. Эндокринология мужской половой системы. Ст-Петербург: ЭЛБИ-СПб 2007; 160.

4. Jost A. Problems of fetal endocrinology: the gonadal and hypophyseal hormones. Recent Prog Horm Res 1953; 8: 379-418.

5. Picard J.Y., Josso N. Purification of testicular anti-Müllerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol Cell Endocrinol 1984; 34: 23-29.

6. Picard J.Y., Benarous R., Guerrier D. et al. Cloning and expression of cDNA for anti-Müllerian hormone. Proc Natl Acad Sci USA 1986; 83: 5464-5468.

7. Cate R.L., Mattaliano R.J., Hession C. et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 1986; 45: 685-698.

8. Cohen-Haguenauer O., Picard J.Y., Mattei M.G. et al. Mapping of the gene for anti-Müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987; 44: 2-6.

9. Clarke T.R., Hoshiya Y., Yi S.E. et al. Müllerian Inhibiting Substance signaling uses a Bone Morphogenetic Protein (BMP)-like pathway mediated by ALK2 and induces Smad6 expression. Mol Endocrinol 2001; 15: 946-959.

10. di Clemente N., Wilson C., Faure E. et al. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone. Mol Endocrinol 1994; 8: 1006-1020.

11. Josso N., di Clemente N., Gouédard L. Anti-Mullerian hormone and its receptors. Mol Cell Endocrinol 2001; 179: 25-32.

12. Klattig J., Englert C. The Müllerian duct: recent insights into its development and regression. Sex Dev 2007; 1: 5: 271-278.

13. Sharpe R.M., McKinnell C., Kivlin C., Fisher J.S. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. Reproduction 2003; 125: 769-784.

14. Lee M.M., Donahoe P.K., Hasegawa T. et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996; 81: 571-576.

15. La Marca A., Broekmans F.J., Volpe A. et al. Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 2009; 24: 9: 2264-2275.

16. di Clemente N., Josso N., Gouedard L., Belville C. Components of the anti-Mullerian hormone signaling pathway in gonads. Mol Cell Endocrinol 2003; 211: 9-14.

17. Visser J.A. AMH signaling: from receptor to target gene. Mol Cell Endocrinol 2003; 211: 65-73.

18. Wang P.Y., Protheroe A., Clarkson A.N. et al. Müllerian inhibiting substance contributes to sex-linked biases in the brain and behavior. Proc Natl Acad Sci USA 2009; 106: 17: 7203-7208.

19. Lebeurrier N., Launay S., Macrez al. Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin. J Cell Sci 2008; 121: 20: 3357-3365.

20. Young J., Rey R., Couzinet B. et al. Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1999; 84: 2696-2699.

21. Young J., Rey R., Schaison G., Chanson P. Hypogonadotropic hypogonadism as a model of post-natal testicular anti-Müllerian hormone secretion in humans. Mol Cell Endocrinol 2003; 211: 1-2: 51-54.

22. Young J., Chanson P., Salenave S. et al. Testicular anti-mullerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90: 2: 724-728.

23. Boukari K., Meduri G., Brailly-Tabard S. et al. Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development. J Clin Endocrinol Metab 2009; 94: 5: 1818-1825.

24. Chemes H.E., Rey R.A., Nistal al. Physiological androgen insensitivity of the fetal, neonatal, and early infantile testis is explained by the ontogeny of the androgen receptor expression in Sertoli cells. J Clin Endocrinol Metab 2008; 93: 11: 4408-4412.

25. Lee M.M., Donahoe P.K., Silverman B.L. et al. Measurements of serum Müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997; 336: 1480-1486.

26. Josso N., Belville C., di Clemente N., Picard J.Y. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Human Reprod Update 2005; 11: 351-356.

27. Belville C., Van Vlijmen H., Ehrenfels C. et al. Mutations of the anti-müllerian hormone gene in patients with persistent müllerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol 2004; 18: 708-721.

28. Brandli D.W., Akbal C., Eugsster al. Persistent Mullerian duct syndrome with bilateral abdominal testis: surgical approach and review of the literature. J Pediatr Urol 2005; 1: 6: 423-427.

29. Josso N., Picard J.Y., Rey R., di Clemente N. Testicular anti-Müllerian hormone: history, genetics, regulation and clinical applications. Pediatr Endocrinol Rev 2006; 3: 4: 347-358.

30. Wuerstle M., Lesser T., Hurwitz R. et al. Persistent mullerian duct syndrome and transverse testicular ectopia: embryology, presentation, and management. J Pediatr Surg 2007; 42: 12: 2116-2119.

31. Beheshti M., Churchill B.M., Hardy B.E. et al. Familial persistent müllerian duct syndrome. J Urol 1984; 131: 968-969.

32. Josso N. Paediatric applications of anti-Müllerian hormone research. 1992 Andrea Prader Lecture. Horm Res 1995; 43: 243-248.

33. Stuchi-Perez E.G., Lukas-Croisier C., De Castro M. et al. Evaluation of the tubular and interstitial functions of the testis in 46,XY patients with ambiguous genitalia. J Pediatr Endocrinol Metab 2000; 13: 605-612.

34. Rey R.A., Belville C., Nihoul-Fekete C. et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab 1999; 84: 2: 627-631.

35. Rey R. Anti-Müllerian hormone in disorders of sex determination and differentiation. Arq Bras Endocrinol Metabol 2005; 49: 1: 26-36.

36. Misra M., MacLaughlin D.T., Donahoe P.K., Lee M.M. The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization. J Clin Endocrinol Metab 2003; 88: 787-792.

37. Martinez-Aguayo A., Rocha A., Rojas N. et al. Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007; 92: 12: 4583-4589.

38. Eldar-Geva T., Hirsch H., Benarroch F. et al. Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. Eur J Endocrinol 2009; 162: 2: 377-384.

39. Hirsch H.J., Eldar-Geva T., Benarroch F. et al. Primary testicular dysfunction is a major contributor to abnormal pubertal development in males with Prader-Willi syndrome. J Clin Endocrinol Metab 2009; 94: 7: 2262-2268.

40. Mostafa T., Amer M.K., Abdel-Malak G. et al. Seminal plasma anti-Müllerian hormone level correlates with semen parameters but does not predict success of testicular sperm extraction (TESE). Asian J Androl 2007; 9: 265-270.

41. Sinisi A.A., Esposito D., Maione L. et al. Seminal anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. Human Reprod 2008; 23: 5: 1029-1034.

42. Laven J.S., Mulders A.G., Visser J.A. et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 1: 318-323.

43. Broekmans F.J., Visser J.A., Laven J.S. et al. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab 2008; 19: 9: 340-347.

44. Chen M.J., Yang W.S., Chen C.L. et al. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 4: 952-957.

45. Shebl O., Ebner T., Sommergruber M. et al. Antimullerian hormone serum levels in women with endometriosis: a case-control study. Gynecol Endocrinol 2009; 25: 11: 713-716.

46. Broer S.L., Mol B.W., Hendriks D., Broekmans F.J. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009; 91: 3: 705-714.

47. Fréour T., Mirallié S., Colombel A. et al. Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol (Paris) 2006; 67: 6: 567-574.

48. La Marca A., Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxford) 2006; 64: 6: 603-610.

Для цитирования:

., . Антимюллеров гормон в дифференцировке, развитии и функции репродуктивной системы. Проблемы Эндокринологии. 2011;57(6):39-44.

For citation:

Ustinkina T.I., Shustov S.B. The role of anti-Mullerian hormone in the differentiation, development, and functioning of the reproductive system. Problems of Endocrinology. 2011;57(6):39-44. (In Russ.)

Просмотров: 17

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)